Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AMG 581 in Healthy Subjects and Subjects With Schizophrenia
NCT02567370Phase 1Completed
- Sponsor
- Amgen
- Start
- Aug 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in schizophrenia comparing AMG 581 with Placebo (2 arms). Primary endpoints: Reported treatment-emergent adverse events at 15 days, Changes in systolic/diastolic blood pressure at 15 days and 7 more. Started Aug 2015; status: completed.
02
Drugs
AMG 581
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02567370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02567370.